๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Noninvasive Markers of Advanced Histology in Nonalcoholic Fatty Liver Disease: Are We There yet?

โœ Scribed by Spencer Wilson; Naga Chalasani

Book ID
119760024
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
66 KB
Volume
133
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Comparison of Noninvasive Markers of Fib
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
โœ Shah, Amy G.; Lydecker, Alison; Murray, Karen; Tetri, Brent N.; Contos, Melissa ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 688 KB

## Background & aims: There is a need for a reliable and inexpensive noninvasive marker of hepatic fibrosis in patients with nonalcoholic fatty liver disease (nafld). we compared the performance of the fib4 index (based on age, aspartate aminotransferase [ast] and alanine aminotransferase [alt] lev

Low circulating levels of dehydroepiandr
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease
โœ Michael Charlton; Paul Angulo; Naga Chalasani; Ralph Merriman; Kimberly Viker; P ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 249 KB

## The biological basis of variability in histological progression of nonalcoholic fatty liver disease (NAFLD) is unknown. Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone and has been shown to influence sensitivity to oxidative stress, insulin sensitivity, and expression of pero

Noninvasive markers of fibrosis in nonal
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
โœ Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cr ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 460 KB ๐Ÿ‘ 1 views

The detection of fibrosis within nonalcoholic fatty liver disease (NAFLD) is important for ascertaining prognosis and the stratification of patients for emerging therapeutic intervention. We validated the Original European Liver Fibrosis panel (OELF) and a simplified algorithm not containing age, th